UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 151

Sortiert nach

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

Annals of oncology, 2002-12, Vol.13 (12), p.1841-1851

2002

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.182-191

2014

Link zum Volltext

Verfügbarkeit prüfen

Race and Ethnicity in Cancer Therapy: What Have We Learned?

Clinical pharmacology and therapeutics, 2014-04, Vol.95 (4), p.403-412

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

Cancer chemotherapy and pharmacology, 2013, Vol.71 (1), p.115-121

2013

Link zum Volltext

Verfügbarkeit prüfen

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer

Annals of oncology, 2002-04, Vol.13 (4), p.539-545

2002

Link zum Volltext

Verfügbarkeit prüfen

Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors

British journal of cancer, 2005-05, Vol.92 (10), p.1922-1926

2005

Link zum Volltext

Verfügbarkeit prüfen

An epigenetic mechanism for capecitabine resistance in mesothelioma

Biochemical and biophysical research communications, 2010-01, Vol.391 (3), p.1465-1470

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1073-1082

2009

Link zum Volltext

Verfügbarkeit prüfen

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study

Annals of oncology, 2008-11, Vol.19 (11), p.1903-1909

2008

Link zum Volltext

Verfügbarkeit prüfen

Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (22), p.1718-1721

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer

Annals of oncology, 2004-06, Vol.15 (6), p.915-920

2004

Link zum Volltext

Verfügbarkeit prüfen

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Annals of oncology, 2001-05, Vol.12 (5), p.605-614

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks

Annals of oncology, 2001-11, Vol.12 (11), p.1631-1641

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

Annals of oncology, 1998-07, Vol.9 (7), p.733-738

1998

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies

Journal of clinical oncology, 1998-08, Vol.16 (8), p.2770-2779

1998

Link zum Volltext

Verfügbarkeit prüfen

RT-PCR Heteroduplex Analysis Permits Differentiation of Transgene and Host Gene Expression in a Transgenic Animal Model

BioTechniques, 2002-07, Vol.33 (1), p.58-66

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Journal of clinical oncology, 1999-02, Vol.17 (2), p.685-696

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2000-12, Vol.18 (24), p.4086-4097

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 1999-06, Vol.17 (6), p.1915-1925

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Journal of clinical oncology, 2001-02, Vol.19 (3), p.857-869

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1095-1104

1999

Link zum Volltext

Verfügbarkeit prüfen

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

Oncogene, 2001-11, Vol.20 (53), p.7787-7796

2001

Link zum Volltext

Verfügbarkeit prüfen

A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors

Investigational new drugs, 2005-12, Vol.23 (6), p.555-562

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2000-01, Vol.18 (1), p.167-177

2000

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema

Annals of oncology, 1998-01, Vol.9 (1), p.71-77

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 151

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(149)
Berichte
(2)

Sprache

Englisch
(151)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(74)
Humans
(72)
Oncology
(60)
Female
(50)
Male
(47)
Middle Aged
(46)
Adult
(42)
Aged
(41)
Biological And Medical Sciences
(41)
Medical Sciences
(38)
Pharmacology. Drug Treatments
(29)
Antineoplastic Agents
(28)
Chemotherapy
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Drug Administration Schedule
(21)
Neoplasms - Drug Therapy
(21)
Dose-Response Relationship, Drug
(20)
Tumors
(19)
Aged, 80 And Over
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity

Erlotinib in African Americans With Advanced Non-Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

Race and Ethnicity in Cancer Therapy: What Have We Learned?

Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer

Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors

An epigenetic mechanism for capecitabine resistance in mesothelioma

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies

Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study

Expression of Pirh2, a Newly Identified Ubiquitin Protein Ligase, in Lung Cancer

A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer

A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies

RT-PCR Heteroduplex Analysis Permits Differentiation of Transgene and Host Gene Expression in a Transgenic Animal Model

Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors

Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies

Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors

Phase I and Pharmacologic Study of PN401 and Fluorouracil in Patients With Advanced Solid Malignancies

A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain edema

Suchergebnisse filtern